並列摘要
Accumulating evidence has demonstrated that the immune system plays a critical role in recognizing, eliminating transformed malignant cells and also in promoting tumor progression. The role of the immune system to suppress and promote cancer growth is termed ＂cancer immunoediting＂ and consists of three phases: elimination, equilibrium, and escape. The success of immune checkpoint blockade and understanding of cell-mediated immunity represents a turning point in cancer immunotherapy. The clinical goal of cancer immunotherapy is to provide either passive or active immunity against malignancies by harnessing the immune system to target tumors. Recently, monoclonal antibodies, cellular immunotherapy, vaccines, immune checkpoint therapy, and chimeric antigen receptor T-cell immunotherapy have increasingly become successful therapeutic agents for the treatment of solid and hematological cancers in clinical practice.
參考文獻
被引用紀錄
延伸閱讀
- 林玉芬、鄭吉元、王昭慧、張文震、陳麗娟、李淑慧（2018）。淺談癌症免疫治療。腫瘤護理雜誌，18(1)，5-11。https://doi.org/10.3966/168395442018061801001
- 高明見、曾振武（2008）。免疫系統與細胞免疫療法：防治癌症的輔助療法。中華民國內膜異位症婦女協會會刊，15(6)，12-14。https://doi.org/10.6498/EA.2008.15(6).5
- 許秉寧（2018）。免疫療法在非癌症的臨床應用。台灣醫學，22(4)，379-379。https://www.airitilibrary.com/Article/Detail?DocID=10281916-201807-201807270004-201807270004-379-379
- 林宗洲（1979）。腫瘤之免疫療法。當代醫學，(68)，526-530。https://doi.org/10.29941/MT.197906.0009
- 陳盈吟、陳崇裕（2019）。Update of Immunotherapy。中西整合醫學雜誌，21(1)，1-7。https://www.airitilibrary.com/Article/Detail?DocID=02119153-201906-201908200007-201908200007-1-7